Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Phase II

Xpira Pharmaceuticals

1 Drug Candidate

Xpira Pharmaceuticals is a Toronto-based private biotech developing psilocybin-assisted therapy for anorexia nervosa (AN), a condition with no currently approved pharmacological or psychotherapeutic treatments. Founded in 2020 by leaders from the Canadian and Dutch pharmaceutical industries, the company received FDA IND approval in September 2022 for a Phase 2a clinical trial. Xpira is a portfolio company of Origin Therapeutics Holdings. Dr. Allan Kaplan of CAMH and the University of Toronto serves as VP of Clinical Development.

Drug Pipeline

1

Psilocybin (oral)

Psilocybin
Phase II
Eating Disorders

Phase 2a psilocybin-assisted therapy for anorexia nervosa; FDA IND approved Sep 2022. AN has no approved pharmacological or psychotherapeutic treatments.

Quick Facts

Type
Private Biotech
Founded
2020
Lead Stage
Phase II
Website
Visit